Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 215 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Valproic Acid (VPA) Clear all

Conditions: Drug Interaction
Interventions: ecopipam HCL, Mefenamic acid, Divalproex Sodium ER; Drug
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Bipolar Disorder
Interventions: Divalproex sodium extended release; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Bipolar Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Schizophrenia
Interventions: Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 35
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Anaheim, California + 32 more

Conditions: Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions: decitabine, valproic acid, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Scleroderma, Systemic Sclerosis
Interventions: Divalproex sodium; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bipolar Disorder, Mania
Interventions: Lithium (LI), Divalproex (DV); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 7
States / cities: Flowood, Mississippi • White Plains, New York • Durham, North Carolina + 4 more

Conditions: Bipolar Disorder
Interventions: Divalproex Sodium (Delayed-Release Tablets), Divalproex Sodium (Extended-Release Tablets), Olanzapine; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 15
States / cities: Anaheim, California • Chula Vista, California • Fort Meyers, Florida + 12 more

Conditions: Autism
Interventions: Divalproex Sodium ER; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions: Valproic acid, Isotonic saline solution; Drug
Lead sponsor: Westat; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: San Francisco, California • Denver, Colorado • Dallas, Texas + 1 more

Conditions: Retinitis Pigmentosa
Interventions: Valproic Acid, Placebo; Drug
Lead sponsor: Foundation Fighting Blindness; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 6
States / cities: Miami, Florida • Ann Arbor, Michigan • Portland, Oregon + 3 more

Conditions: Solid Tumors
Interventions: Azacitidine, Valproic Acid, Carboplatin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alcohol Dependence, Alcohol Withdrawal Syndrome, Trauma, Heavy Drinking, Alcohol Use Disorder
Interventions: Valproate, Lorazepam; Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Charleston, West Virginia

Conditions: Elderly, Epilepsy, Seizures
Interventions: Divalproex Sodium Extended-Release Tablets; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 60 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy
Interventions: divalproex sodium, Depakote®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Thyroid Neoplasm
Interventions: Valproic Acid, Liothyronine Sodium; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Temsirolimus, Valproic Acid; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 2 Years to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Charlotte, North Carolina

Conditions: Bipolar Disorder
Interventions: Fluoxetine, Citalopram; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Disorder
Interventions: olanzapine, divalproex sodium, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 31
States / cities: Scottsdale, Arizona • Beverly Hills, California • Costa Mesa, California + 28 more

Conditions: Healthy
Interventions: divalproex sodium; Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 54 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Mood Disorder
Interventions: Valproic Acid and Depakote ER; Drug
Lead sponsor: Joliet Center for Clinical Research; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Joliet, Illinois

Conditions: Solid Tumors
Interventions: Dasatinib, Erlotinib, Lapatinib, Lenalidomide, Sorafenib, Sunitinib, Valproic Acid; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: DEPAKOTE® Tablets, 500 MG, DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Mania, Bipolar Disorder
Interventions: Xanomeline/Trospium Chloride, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 22
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 19 more

Search by objective public record fields.

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

Safety And Efficacy Study Of Depakote ER To Treat Pediatric Bipolar Disorder

12- Week Open Label Treatment of Refractory Bipolar Depression

Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia

Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma

Treatment of Bipolar Mania in Older Adults

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

Divalproex Sodium ER in Adult Autism

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients

Trial of Oral Valproic Acid for Retinitis Pigmentosa

Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

Assessment of Valproate on Ethanol Withdrawal

Tolerability and Efficacy of Depakote-extended Release in the Elderly

Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions

A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin

Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma

Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging

Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation

Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar Tients From Valproic Acid to Depakote ER

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine